Real-world evidence evaluating continuation of CDK4/6 inhibitors beyond first progression in hormone receptor-positive (HR+) metastatic breast cancer.

Akaolisa Samuel Eziokwu,Leticia Varella,Megan Kruse,Xuefei Jia,Halle C. F. Moore,George Thomas Budd,Jame Abraham,Alberto J. Montero

Real-world evidence evaluating continuation of CDK4/6 inhibitors beyond first progression in hormone receptor-positive (HR+) metastatic breast cancer.

2019

Akaolisa Samuel Eziokwu
Leticia Varella
Megan Kruse
Xuefei Jia
Halle C. F. Moore
George Thomas Budd
Jame Abraham
Alberto J. Montero

e12538Background: CDK inhibitors (CDKi), in combination with aromatase inhibitors (AI), are approved for the treatment of hormone receptor positive (HR+) Her2 negative metastatic breast cancer (MBC...

Keywords:

Hormone receptor
Pathology
Oncology
Metastatic breast cancer
Internal medicine
Medicine
HER2 negative
Aromatase
real world evidence
Cyclin-dependent kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations